Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.
BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...
First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...
PhotonPharma Inc., a biopharmaceutical company pioneering personalized cancer immunotherapies, today announced that patient recruitment has opened for its Phase 1 clinical trial evaluating Innocell™ ...
Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
Oranges aren’t the only immune-supporting food. Red bell peppers, spinach, papaya, and ginger also provide key nutrients for ...
Onchilles Pharma Announces IND Clearance for N17350, Advancing the First Next-Gen Cytotoxic Therapeutic Leveraging the ELANE ...
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic ...
POSTECH and ImmunoBiome researchers uncover a novel microbiota-Tfh cell axis to enhance antibody production and mucosal ...
Modern disease is complex and individual. Biopharma offers a biological approach to more precise, effective treatment ...
The trial is conducted at the Mays Cancer Center, part of the University of Texas at San Antonio’s Health Science Center.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results